Jeremy is an oncological surgeon with primary interest in bladder cancer. Previously, he conducted a randomised trial showing that bipolar transurethral resection of bladder tumour (TURBT) was able to achieve a higher detrusor sampling rate than monopolar TURBT. He has also developed a global consensus statement on en bloc resection of bladder tumour (ERBT). The consensus statement has become the standard reference for urologists practising en bloc resection globally. In 2024, he published the results of the EB-StaR study, which is a multi-centre randomised trial demonstrating that ERBT could reduce the 1-year recurrence rate from 38.1% to 28.5% for patients with ≤3cm non-muscle-invasive bladder cancer (NMIBC). He completed a phase 2 clinical trial on modified en bloc resection for large bladder tumours (>3cm), showing that modified ERBT could achieve a >90% rate of complete resection for NMIBC and proper staging for MIBC. He is also leading the Global ERBT Registry, which has >100 centres joining and >3000 patients being recruited so far. He is currently serving as a panel member of the European Association of Urology (EAU) Guidelines on NMIBC and Upper Tract Urothelial Carcinoma. He is also serving as an Associate Editor for the prestigious journal European Urology Oncology.
